Experimentally Increasing the Compliance of Titin Through RNA Binding Motif-20 (RBM20) Inhibition Improves Diastolic Function in a Mouse Model of Heart Failure with Preserved Ejection Fraction

Circulation

Volumn 134, Issue 15, 2016, Pages 1085-1099

  Methawasin, Mei ^a   Strom, Joshua G ^a   Slater, Rebecca E ^a   Fernandez, Vanessa ^a   Saripalli, Chandra ^a   Granzier, Henk ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

compliance; diastole; heart failure

Indexed keywords

CONNECTIN; RALOXIFENE; RNA BINDING MOTIF 20; RNA BINDING PROTEIN; UNCLASSIFIED DRUG; RBM20 PROTEIN, MOUSE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; EXERCISE; EXERCISE TEST; EXERCISE TOLERANCE; EXTRACELLULAR MATRIX; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MUSCLE; MOUSE; MUSCLE RIGIDITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RIGIDITY; UPREGULATION; ANIMAL; COMPLIANCE (PHYSICAL); DIASTOLE; DISEASE MODEL; GENETICS; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RNA-BINDING DOMAIN; TRANSGENIC MOUSE;

ANIMALS; COMPLIANCE; CONNECTIN; DIASTOLE; DISEASE MODELS, ANIMAL; EXERCISE TOLERANCE; HEART FAILURE; HYPERTROPHY, LEFT VENTRICULAR; MICE; MICE, TRANSGENIC; RNA-BINDING MOTIFS; RNA-BINDING PROTEINS; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 84988643265     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.023003     Document Type: Article

References (47)

1. Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11:507-515. doi: 10.1038/nrcardio.2014.83.
2. van Heerebeek L, Franssen CP, Hamdani N, Verheugt FW, Somsen GA, Paulus WJ. Molecular and cellular basis for diastolic dysfunction. Curr Heart Fail Rep. 2012;9:293-302. doi: 10.1007/ s11897-012-0109-5.
3. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32:670-679. doi: 10.1093/eurheartj/ehq426.
4. LeWinter MM, Meyer M. Mechanisms of diastolic dysfunction in heart failure with a preserved ejection fraction: if it's not one thing it's another. Circ Heart Fail. 2013;6:1112-1115. doi: 10.1161/ CIRCHEARTFAILURE.113.000825.
5. Basaraba JE, Barry AR. Pharmacotherapy of heart failure with preserved ejection fraction. Pharmacotherapy. 2015;35:351-360. doi: 10.1002/phar.1556.
6. Nanayakkara S, Kaye DM. Management of heart failure with preserved ejection fraction: a review. Clin Ther. 2015;37:2186-2198. doi: 10.1016/j.clinthera.2015.08.005.
7. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263-271. doi: 10.1016/j.jacc.2013.02.092.
8. Chung CS, Granzier HL. Contribution of titin and extracellular matrix to passive pressure and measurement of sarcomere length in the mouse left ventricle. J Mol Cell Cardiol. 2011;50:731-739. doi: 10.1016/j.yjmcc.2011.01.005.
9. Granzier HL, Irving TC. Passive tension in cardiac muscle: contribution of collagen, titin, microtubules, and intermediate filaments. Biophys J. 1995;68:1027-1044. doi: 10.1016/S0006-3495(95)80278-X.
10. Borbély A, van der Velden J, Papp Z, Bronzwaer JG, Edes I, Stienen GJ, Paulus WJ. Cardiomyocyte stiffness in diastolic heart failure. Circulation. 2005;111:774-781. doi: 10.1161/01. CIR.0000155257.33485.6D.
11. Zile MR, Baicu CF, Ikonomidis JS, Stroud RE, Nietert PJ, Bradshaw AD, Slater R, Palmer BM, Van Buren P, Meyer M, Redfield MM, Bull DA, Granzier HL, LeWinter MM. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015;131:1247-1259. doi: 10.1161/CIRCULATIONAHA.114.013215.
12. Borbély A, Falcao-Pires I, van Heerebeek L, Hamdani N, Edes I, Gavina C, Leite-Moreira AF, Bronzwaer JG, Papp Z, van der Velden J, Stienen GJ, Paulus WJ. Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circ Res. 2009;104:780-786. doi: 10.1161/CIRCRESAHA. 108.193326.
13. Nagueh SF, Shah G, Wu Y, Torre-Amione G, King NM, Lahmers S, Witt CC, Becker K, Labeit S, Granzier HL. Altered titin expression, myocardial stiffness, and left ventricular function in patients with dilated cardiomyopathy. Circulation. 2004;110:155-162. doi: 10.1161/01.CIR.0000135591.37759.AF.
14. Makarenko I, Opitz CA, Leake MC, Neagoe C, Kulke M, Gwathmey JK, del Monte F, Hajjar RJ, Linke WA. Passive stiffness changes caused by upregulation of compliant titin isoforms in human dilated cardiomyopathy hearts. Circ Res. 2004;95:708-716. doi: 10.1161/01.RES.0000143901.37063.2f.
15. Greaser ML, Krzesinski PR, Warren CM, Kirkpatrick B, Campbell KS, Moss RL. Developmental changes in rat cardiac titin/ connectin: transitions in normal animals and in mutants with a delayed pattern of isoform transition. J Muscle Res Cell Motil. 2005;26:325-332. doi: 10.1007/s10974-005-9039-0.
16. Greaser ML, Warren CM, Esbona K, Guo W, Duan Y, Parrish AM, Krzesinski PR, Norman HS, Dunning S, Fitzsimons DP, Moss RL. Mutation that dramatically alters rat titin isoform expression and cardiomyocyte passive tension. J Mol Cell Cardiol. 2008;44:983-991. doi: 10.1016/j.yjmcc.2008.02.272.
17. Guo W, Schafer S, Greaser ML, Radke MH, Liss M, Govindarajan T, Maatz H, Schulz H, Li S, Parrish AM, Dauksaite V, Vakeel P, Klaassen S, Gerull B, Thierfelder L, Regitz-Zagrosek V, Hacker TA, Saupe KW, Dec GW, Ellinor PT, MacRae CA, Spallek B, Fischer R, Perrot A, Özcelik C, Saar K, Hubner N, Gotthardt M. RBM20, a gene for hereditary cardiomyopathy, regulates titin splicing. Nat Med. 2012;18:766-773. doi: 10.1038/nm.2693.
18. Methawasin M, Hutchinson KR, Lee EJ, Smith JE 3rd, Saripalli C, Hidalgo CG, Ottenheijm CA, Granzier H. Experimentally increasing titin compliance in a novel mouse model attenuates the Frank-Starling mechanism but has a beneficial effect on diastole. Circulation. 2014;129:1924-1936. doi: 10.1161/CIRCULATIONAHA. 113.005610.
19. Mohammed SF, Ohtani T, Korinek J, Lam CS, Larsen K, Simari RD, Valencik ML, Burnett JC Jr, Redfield MM. Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects." Circulation. 2010;122:370-378. doi: 10.1161/CIRCULATIONAHA.109.915215.
20. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:1810-1852. doi: 10.1161/CIR.0b013e31829e8807.
21. Sohal DS, Nghiem M, Crackower MA, Witt SA, Kimball TR, Tymitz KM, Penninger JM, Molkentin JD. Temporally regulated and tissuespecific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. Circ Res. 2001;89:20-25.
22. Hu P, Zhang D, Swenson L, Chakrabarti G, Abel ED, Litwin SE. Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload. Am J Physiol Heart Circ Physiol. 2003;285:H1261-H1269. doi: 10.1152/ajpheart. 00108.2003.
23. Radke MH, Peng J, Wu Y, McNabb M, Nelson OL, Granzier H, Gotthardt M. Targeted deletion of titin N2B region leads to diastolic dysfunction and cardiac atrophy. Proc Natl Acad Sci U S A. 2007;104:3444-3449. doi: 10.1073/pnas.0608543104.
24. Burkhoff D, Mirsky I, Suga H. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol. 2005;289:H501-H512. doi: 10.1152/ajpheart. 00138.2005.
25. O'Connell TD, Rodrigo MC, Simpson PC. Isolation and culture of adult mouse cardiac myocytes. Methods Mol Biol. 2007;357:271-296. doi: 10.1385/1-59745-214-9:271.
26. King NM, Methawasin M, Nedrud J, Harrell N, Chung CS, Helmes M, Granzier H. Mouse intact cardiac myocyte mechanics: crossbridge and titin-based stress in unactivated cells. J Gen Physiol. 2011;137:81-91. doi: 10.1085/jgp.201010499.
27. Wu Y, Cazorla O, Labeit D, Labeit S, Granzier H. Changes in titin and collagen underlie diastolic stiffness diversity of cardiac muscle. J Mol Cell Cardiol. 2000;32:2151-2162. doi: 10.1006/ jmcc.2000.1281.
28. Lahmers S, Wu Y, Call DR, Labeit S, Granzier H. Developmental control of titin isoform expression and passive stiffness in fetal and neonatal myocardium. Circ Res. 2004;94:505-513. doi: 10.1161/01.RES.0000115522.52554.86.
29. Hudson BD, Hidalgo CG, Gotthardt M, Granzier HL. Excision of titin's cardiac PEVK spring element abolishes PKCalpha-induced increases in myocardial stiffness. J Mol Cell Cardiol. 2010;48:972-978. doi: 10.1016/j.yjmcc.2009.12.006.
30. Little WC, Ohno M, Kitzman DW, Thomas JD, Cheng CP. Determination of left ventricular chamber stiffness from the time for deceleration of early left ventricular filling. Circulation. 1995;92:1933-1939.
31. Ohno M, Cheng CP, Little WC. Mechanism of altered patterns of left ventricular filling during the development of congestive heart failure. Circulation. 1994;89:2241-2250.
32. Jacques DC, Pinsky MR, Severyn D, Gorcsan J 3rd. Influence of alterations in loading on mitral annular velocity by tissue Doppler echocardiography and its associated ability to predict filling pressures. Chest. 2004;126:1910-1918. doi: 10.1378/chest.126.6.1910.
33. Garcia MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol. 1998;32:865-875.
34. Toischer K, Rokita AG, Unsöld B, Zhu W, Kararigas G, Sossalla S, Reuter SP, Becker A, Teucher N, Seidler T, Grebe C, Preuss L, Gupta SN, Schmidt K, Lehnart SE, Krüger M, Linke WA, Backs J, Regitz-Zagrosek V, Schäfer K, Field LJ, Maier LS, Hasenfuss G. Differential cardiac remodeling in preload versus afterload. Circulation. 2010;122:993-1003. doi: 10.1161/CIRCULATIONAHA. 110.943431.
35. Perkin J, Slater R, Del Favero G, Lanzicher T, Hidalgo C, Anderson B, Smith JE 3rd, Sbaizero O, Labeit S, Granzier H. Phosphorylating titin's cardiac N2B element by ERK2 or CaMKII? lowers the single molecule and cardiac muscle force. Biophys J. 2015;109:2592-2601. doi: 10.1016/j.bpj.2015.11.002.
36. Kobirumaki-Shimozawa F, Oyama K, Shimozawa T, Mizuno A, Ohki T, Terui T, Minamisawa S, Ishiwata S, Fukuda N. Nano-imaging of the beating mouse heart in vivo: importance of sarcomere dynamics, as opposed to sarcomere length per se, in the regulation of cardiac function. J Gen Physiol. 2016;147:53-62. doi: 10.1085/ jgp.201511484.
37. Granzier HL, Radke MH, Peng J, Westermann D, Nelson OL, Rost K, King NM, Yu Q, Tschöpe C, McNabb M, Larson DF, Labeit S, Gotthardt M. Truncation of titin's elastic PEVK region leads to cardiomyopathy with diastolic dysfunction. Circ Res. 2009;105:557-564. doi: 10.1161/CIRCRESAHA.109.200964.
38. Linke WA, Hamdani N. Gigantic business: titin properties and function through thick and thin. Circ Res. 2014;114:1052-1068. doi: 10.1161/CIRCRESAHA.114.301286.
39. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E; RELAX Trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309:1268-1277. doi: 10.1001/jama.2013.2024.
40. LeWinter MM, Granzier H. Cardiac titin: a multifunctional giant. Circulation. 2010;121:2137-2145. doi: 10.1161/CIRCULATIONAHA. 109.860171.
41. Yu CM, Fung WH, Lin H, Zhang Q, Sanderson JE, Lau CP. Predictors of left ventricular reverse remodeling after cardiac resynchronization therapy for heart failure secondary to idiopathic dilated or ischemic cardiomyopathy. Am J Cardiol. 2003;91:684-688.
42. Markowitz SM, Lewen JM, Wiggenhorn CJ, Abraham WT, Stein KM, Iwai S, Lerman BB. Relationship of reverse anatomical remodeling and ventricular arrhythmias after cardiac resynchronization. J Cardiovasc Electrophysiol. 2009;20:293-298. doi: 10.1111/j.1540-8167.2008.01317.x.
43. Kartal Y, Yavuzgil O, Bozoglu M, Alp A, Can LH, Hasdemir C. Cardiac resynchronization therapy with or without anatomical reverse remodeling does not affect defibrillation threshold. Pacing Clin Electrophysiol. 2012;35:416-421. doi: 10.1111/j.1540-8159.2011.03326.x.
44. Shetty AK, Duckett SG, Ginks MR, Ma Y, Sohal M, Bostock J, Kapetanakis S, Singh JP, Rhode K, Wright M, O'Neill MD, Gill JS, Carr-White G, Razavi R, Rinaldi CA. Cardiac magnetic resonancederived anatomy, scar, and dyssynchrony fused with fluoroscopy to guide LV lead placement in cardiac resynchronization therapy: a comparison with acute haemodynamic measures and echocardiographic reverse remodelling. Eur Heart J Cardiovasc Imaging. 2013;14:692-699. doi: 10.1093/ehjci/jes270.
45. Redfield MM, Borlaug BA, Lewis GD, Mohammed SF, Semigran MJ, Lewinter MM, Deswal A, Hernandez AF, Lee KL, Braunwald E; Heart Failure Clinical Research Network. PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. Circ Heart Fail. 2012;5:653-659. doi: 10.1161/CIRCHEARTFAILURE. 112.969071.
46. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E; RELAX Trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309:1268-1277. doi: 10.1001/jama.2013.2024.
47. Maatz H, Jens M, Liss M, Schafer S, Heinig M, Kirchner M, Adami E, Rintisch C, Dauksaite V, Radke MH, Selbach M, Barton PJ, Cook SA, Rajewsky N, Gotthardt M, Landthaler M, Hubner N. RNAbinding protein RBM20 represses splicing to orchestrate cardiac pre-mRNA processing. J Clin Invest. 2014;124:3419-3430. doi: 10.1172/JCI74523.